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Abstract Acute ischemic injury and chronic cardiomyop-
athies can cause irreversible loss of cardiac tissue leading to
heart failure. Cellular therapy offers a new paradigm for
treatment of heart disease. Stem cell therapies in animal
models show that transplantation of various cell prepara-
tions improves ventricular function after injury. The first
clinical trials in patients produced some encouraging
results, despite limited evidence for the long-term survival
of transplanted cells. Ongoing research at the bench and the
bedside aims to compare sources of donor cells, test
methods of cell delivery, improve myocardial homing,
bolster cell survival, and promote cardiomyocyte differen-
tiation. This article reviews progress toward these goals.
Keywords HeartFailure.MyocardialInfarction.
StemCells.CellTherapy.CardiacRegeneration
Cardiovascular disease remains the leading cause of death
worldwide. Current therapies seek to prevent atherosclerosis
through risk factor modification and to manage the con-
sequences of thrombosis after injury has occurred. Regener-
ative medicine offers a new paradigm for treatment of heart
disease. Stem cell therapies may improve ventricular
function after injury through either direct or indirect means,
by engraftment and differentiation into cardiac and vascular
cells or by secretion of paracrine factors that promote tissue
survival and recovery. Thus far, the results of animal studies
and clinical trials have been encouraging, despite limited
evidence for the long-term survival of transplanted cells.
In contrast to conventional therapies where defined
pipelines lead from target identification to drug discovery
and development, cardiovascular cell therapies are evolving
by a much more diffuse process, more akin to a group of
investigators working to solve a puzzle. Pieces of this cell
therapy puzzle may now be defined, so that they can be
refined and assembled through ongoing study and collab-
oration. These pieces include (1) the cell types available for
transplant, (2) the methods of cell delivery, (3) the means of
myocardial homing, (4) the pathways of cell survival, and
(5) the goals of cell differentiation.
Stem Cell Populations with Potential for Cardiac
Regeneration
Over the past decade, many cell types have been evaluated
in an effort to find the best source for cardiac regeneration.
Of these, the most extensively studied have been embryonic
stem cells, mesenchymal stem cells, skeletal myoblasts, and
bone marrow-derived progenitor cells, while more recent
possibilities have included induced pluripotent stem cells
and resident cardiac stem cells.
Embryonic stem cells (ESCs) can be obtained from the
inner cell mass of a pre-implantation blastocyst and
expanded in vitro almost indefinitely without loss of
pluripotency [1–3]. When allowed to differentiate as
embryoid bodies, ESCs give rise to most somatic lineages,
including cardiovascular lineages [4–8]. Culture of em-
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molecules can drive differentiation toward cardiovascular
phenotypes, thereby enriching the pool of ESC-derived
cardiac cells available for transplant [8–13]. Both plurip-
otent ESCs and committed ESC-derived cardiac cells have
been tested in rodent models with encouraging results in
terms of engraftment, survival, and improvement in
ventricular function [14–16]. However, no clinical trials
have been attempted, for concerns of teratoma formation
[16, 17], graft-versus-host disease [18], and bioethics.
While improved in vitro differentiation of ESCs may
eliminate the first of these concerns, recent discoveries
indicating that adult somatic cells can be reprogrammed to
yield ESC-like cells may eliminate the second and third of
these issues.
Induced pluripotent stem cells (iPSCs) can be generated
from murine and human adult somatic cells by over-
expression of transcription factors critical for maintenance
of ESC pluripotency. While initial iPSC protocols required
retro- or lentiviral transfer of four factors, namely Octamer-
binding transcription factor 3/4 (Oct 3/4), Sry-related
HMG-box transcription factor (Sox2), Krüppel-like factor
4, and cellular myelocytomatosis oncogene [19, 20] or Oct
3/4, Sox2, Nanog, and Lin28 [21], subsequent reports have
reduced the risk of tumorigenesis introduced during the de-
differentiation process by utilizing non-integrating technol-
ogies [22–25] or by transferring fewer transcription factors
[26–28] while still achieving pluripotency. Once estab-
lished, iPSCs differentiate much like ESCs, yielding
functional cardiovascular lineages from embryoid bodies
in vitro [28–32] and contributing to normal cardiovascular
development from chimeric blastocysts in vivo [28, 31, 33].
In an initial proof-of-principle study, four-factor iPSCs
successfully restored myocardial structure and function
after coronary artery ligation in mice [33]. Thus, iPSCs
may provide an unlimited supply of autologous donor cells,
once technological advancements eliminate the risk of
teratoma or other tumor formation.
Mesenchymal stem cells (MSCs) can be separated from
bone marrow and adipose tissues based on their adherence
to a culture dish [34]. MSCs most readily differentiate into
osteoblasts, chondrocytes, and adipocytes [35, 36] but can
be induced to differentiate into cardiomyocytes under
special conditions [37–39]. They can be rapidly expanded
in culture, thereby allowing for autologous transplantation,
and they may be less immunogenic than other cell popu-
lations, thereby allowing for allogenic transplantation
[40, 41]. But, their propensity to differentiate into non-
cardiac tissues (e.g., heterotopic ossification) currently
limits their use [42, 43]. Nonetheless, at least one clinical
trial has shown improved ventricular function at 3 and
6 month follow-up after intracoronary infusion of autolo-
gous MSCs postinfarction [44].
Skeletal myoblasts, also known as satellite cells, can be
harvested from muscle biopsies, expanded in culture, and
autologously reimplanted, albeit on a timescale more
appropriate for chronic heart failure therapy than for early
postinfarction management. As these cells are further
differentiated than ESCs, they are less prone to teratoma
formation; they are also more resistant to ongoing ischemia
and more apt to function in a contractile capacity
postengraftment. However, true cardiomyocyte differentia-
tion has not been observed in vivo. As a result, although
skeletal myoblasts may be incorporated into an infarct site,
their contractions are dyssynchronous due to failure of
electromechanical coupling with the surrounding myocar-
dium [45, 46]. Thus, no significant benefit has been seen in
large-scale clinical trials, while a trend toward more
frequent arrhythmias has been observed [47].
Bone marrow-derived mononuclear cells, including
hematopoietic and endothelial progenitor cells, can
be mobilized with cytokine therapy or harvested by stan-
dard collection techniques. In culture, they can differen-
tiate into cardiomyocytes, endothelial cells, and smooth
muscle cells [48–51], and after transplant, they can supply
a broad range of paracrine factors with proangiogenic,
positive remodeling, and antiapoptotic properties [52]. A
meta-analysis of 18 randomized and non-randomized trials
involving 999 patients with acute myocardial infarction or
chronic ischemic cardiomyopathy found that intracoronary
infusion of adult bone marrow-derived stem cells im-
proved left ventricular ejection fraction by 3.7%, de-
creased infarct scar size by 5.5%, and lowered left
ventricular end-systolic volume by 4.8 ml (p<0.01 for
each index) [53]. Among these pooled studies, the largest
randomized trial, REPAIR-AMI, was particularly notable
for not only demonstrating improvement in ventricular
function but also for reducing the combined endpoint
of death, myocardial infarction, or revascularization
at 12 months when compared with placebo [54]. None-
theless, controversy remains regarding the fates of
bone marrow-derived cells used for cardiac regeneration
[55].
Spatiotemporal Aspects of Stem Cell Delivery
Identification of the most safe and efficacious means of
stem cell delivery remains an important challenge, both in
terms of route and timing of administration. Current
methods of stem cell delivery include non-invasive mobi-
lization from resident niches (especially bone marrow) with
cytokine therapy, non-selective intravenous or intracavitary
injection, selective intracoronary infusion, and intramyo-
cardial injection from either surgical or percutaneous
access.
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derived stem cells do home to the infarct border zone, only
a small fraction (<5%) of intravenously injected cells is
retained in this intended destination. Rather, the majority of
intravenously injected cells are trapped by the lungs, liver,
kidneys, and spleen [56, 57]. More proximal but still non-
selective delivery via intracavitary or intra-aortic (with the
distal aorta occluded) injection marginally improves cardiac
uptake [56, 57], suggesting that closer may be better. Such
reasoning underlies the majority of clinical trials which
have used intracoronary delivery techniques. Indeed, intra-
coronary delivery appears superior to intravenous delivery
in man [58, 59], although overall cell retention remains low
as rapid washout follows balloon deflation [60]. Clinical
trials assessing the biodistribution of infused cells have
recently been reviewed [61].
In animal studies, intramyocardial delivery yields better
retention than intracoronary delivery [57, 62, 63]. But so
far, no clinical trial has directly compared these two
modalities, although such results should be forthcoming
[64]. In theory, intramyocardial delivery may provide more
precisely targeted therapy without need for patent coronary
arteries, while intracoronary delivery may benefit from
operator familiarity and lower cost. Since intramyocardial
injections carry risk of myocardial perforation and electrical
instability shortly after infarction, these two strategies in
fact may be complementary, with intracoronary cell
delivery provided early and intramyocardial cell delivery
provided late.
Despite the potential importance of correctly timing stem
cell administration, few studies have directly addressed this
issue. On one hand, stem cell survival may be compromised
shortly after infarction by transient microvascular obstruc-
tion, recurrent ischemia, or reperfusion injury. On the other
hand, stem cell homing to the infarct border zone may be
enhanced shortly after injury by transient upregulation of
cytokines such as stromal cell-derived factor 1 (SDF-1),
vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and monocyte chemotactic protein-3
(MCP-3) [65–68]. In rodents, this latter phenomenon
appears to have the upper hand, as the benefits of MSC
therapy are seen only when administered within 4 days
postmyocardial infarction, paralleling myocardial SDF-1
expression [67].
In man, the optimum timing of stem cell therapy may
be different. So far, stem cell administration within 1 day
of reperfusion therapy has not shown clinical benefit [69].
Therefore, the NIH Cardiovascular Cell Therapy Research
Network's TIME trial will compare an early time point of
3 days postmyocardial infarction to an intermediate time
point of 7 days postmyocardial infarction for intracoronary
stem cell infusion [ [70]; http://ccct.sph.uth.tmc.edu/cctrn/
Public/PublicHome.aspx]. This trial will run in parallel
with a related study called LATE-TIME, which will focus
o nal a t et i m ep o i n to f2 –3 weeks postmyocardial
infarction for intracoronary cell infusion. Beyond that
time point, a recent substudy of the MYSTAR trial found
no significant differences in the long-term improvements
in infarct size and ventricular function observed after bone
marrow mononuclear cell delivery at 3–6 weeks versus 3–
4 months [71].
Means of Improving Myocardial Homing
Treatments designed to improve stem cell homing to
diseased myocardium have the potential to markedly
enhance both the safety and efficacy of cardiovascular cell
therapy. By increasing cardiac retention, stem cell capture
by non-cardiac tissues may be reduced, thereby limiting
potential side effects. This may allow stem cell dosages to
be increased, even as outcomes on a per cell basis are
improved. Alternatively, decreased stem cell numeric
requirements may reduce cell culture and delivery costs.
Many current strategies to improve cardiovascular
homing aim to enhance adhesion protein and cytokine
interactions between donor cells and host tissues. Ex vivo
conditioning of donor cells, for example, by incubation of
endothelial progenitor cells with a β2-integrin activating
antibody, can improve retention and transcapillary migra-
tion at sites of injury, where intracellular adhesion
molecule-1 (ICAM-1) and fibrinogen are upregulated [72].
Alternatively, in vivo conditioning of the host vasculature,
for example, by infusion of adenosine, can promote cardiac
retention of endothelial progenitor cells by upregulating
coronary artery expression of P-selectin [73]. Increased
display of this cell adhesion protein captures endothelial
progenitor cells that constitutively express P-selectin
glycoprotein ligand-1 [73, 74]. Adenosine can be safely
infused into the human coronary circulation [75]; thus, it
could be an adjuvant to many existing cell therapy
protocols.
Other potential homing agents remain in pre-clinical
development. These include master regulators of ischemic
responsiveness such as integrin-linked kinase (ILK) and
hypoxia inducible factor-1α (HIF-1α), as well as secreted
homing factors such as SDF-1, MCP-3, and VEGF. In
response to hypoxia, ILK is stabilized by heat shock protein
90. Increased ILK activity then leads to increased expres-
sion of SDF-1 and ICAM-1 through HIF-1α- and nuclear
factor κB-mediated signaling [76]. This results in endothe-
lial progenitor cell recruitment to ischemic tissues [76].
While this beneficial property of ILK has been demonstrat-
ed only in a hindlimb ischemia model thus far, its cardiac
application is likely not far off. Already, it is known that
SDF-1 recruits endothelial progenitor cells expressing
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to its receptor, β2 integrin, on endothelial progenitor cells is
required for engraftment after myocardial infarction [77].
Therefore, given the functional improvements seen with
ILK gene therapy after coronary artery ligation in rats [78],
utilization of ILK in stem cell therapy would seem a logical
step.
Indeed, encouraging results have been obtained when
local myocardial therapy has been combined with stem cell
transplantation. Downstream of ILK, HIF-1α regulates both
SDF-1 and its receptor CXCR4, as well as ICAM-1 [76, 79,
80]. Combining intramyocardial injection of adenovirus-
encoded HIF-1α with transplantation of skeletal myoblasts
results in improved cell engraftment and cell survival after
coronary artery ligation in rats [81]. This results in marked
improvement in ejection fraction (by 27%) at 1 month
posttherapy over baseline at 1 week postinfarct. In
comparison, monotherapy with HIF-1α or myoblasts alone
serves only to prevent further decline of the ejection
fraction over this interval [81].
Further down this ischemic response pathway, both
SDF-1 and its receptor CXCR4 have been used success-
fully as adjuncts to cardiac cell therapy. In mice, endoge-
nous SDF-1 is upregulated for less than 1 week after
myocardial infarction [65–67]. Re-establishment of SDF-1
expression at later time points can enhance stem cell
recruitment and retention when the ischemic border zone
might be less hostile to cell engraftment and survival.
Indeed, intramyocardial delivery of scaffold-bound SDF-1
after coronary artery ligation in rats and mice results in
enhanced c-Kit+ cell homing and improved ventricular
function [82, 83].
Cell-based gene therapy can provide a similar biological
scaffold. While it may seem counterintuitive for a stem cell
to deliver its own homing factor, considerable benefit has
been obtained when genetically modified stem cells recruit
additional native and transplanted cells to injured myocar-
dium. For example, improved cell engraftment and surviv-
al, as well as improved ventricular function, has been
observed after transplantation of SDF-1−expressing skeletal
myoblasts (as opposed to unmodified skeletal myoblasts) at
both early and late time points after myocardial infarction
in rats [84, 85]. Similarly, transplantation of SDF-1-
expressing cardiac fibroblasts promotes homing of endog-
enous CD117+ stem cells to injured myocardium [65]. This
results in improved ventricular function even without
cardiomyocyte regeneration [65]. Rather, improved engraft-
ment and differentiation of transplanted SDF-1-expressing
MSCs (as opposed to unmodified MSCs) into myofibro-
blasts, but not true cardiomyocytes, results in improved
ventricular function by providing trophic support for
cardiomyocyte preservation—but not regeneration—after
infarction [86]. Similar results are obtained after transplan-
tation of CXCR4-overexpressing MSCs [87], indicating
that improved stem cell homing, engraftment, and paracrine
activity can be obtained via cell-based gene therapy with
both stem cell homing factors and their receptors.
Other growth factor–chemokine-receptor pairs, which
may be utilized to improve outcomes of cardiac cell therapy,
include VEGF−Flk-1, HGF−c-Met, MCP-3−CCR1/2, and
growth-related oncogene-1−CXCR1/2 [66, 68, 88–91]. Of
these, the most extensively studied factor is VEGF. VEGF is
transiently upregulated after myocardial infarction [66]a n d
serves to mobilize endothelial progenitor cells while pro-
moting neovascularization [92, 93]. VEGF is both induced
by SDF-1 and an inducer of SDF-1's receptor CXCR4 [94–
96]. Early clinical trials demonstrated that intramyocardial
delivery of naked plasmid-encoded VEGF gene therapy is
safe but results in only marginal clinical benefit [97, 98].
Subsequent human and large animal studies of combination
intramyocardial VEGF gene delivery plus stem cell therapy
have yielded mixed results [99–101]. Meanwhile, VEGF-
transfected stem cells have consistently outperformed
untransfected control cells after coronary artery ligation in
rodents [102–107]. And in those studies that have compared
cell-based gene therapy to direct gene delivery, VEGF-
transfected skeletal myoblasts and VEGF-transfected MSCs
have improved ventricular function to a greater degree than
either direct adenoviral injection or liposomal plasmid
delivery, respectively [106, 107]. Taken together, these
results suggest that cell-based gene therapy may be more
effective than either unmodified stem cell therapy or
acellular gene therapy alone. The degree to which this
principle is generalizable remains to be seen.
Enhancement of Transplanted Cell Survival
Despite the structural and functional benefits of stem cell
therapy in animal and human studies of acute myocardial
infarction and chronic heart failure, limited transplanted cell
survival has been observed, especially in the long-term.
Less than 1% of transplanted cells survive in patient hearts
[108], and even in the idealized scenario of syngeneic
neonatal cardiomyocyte intramyocardial injection in
healthy rats, only 15% of transplanted cells survive for
12 weeks [109]. Nonetheless, recent discoveries demon-
strative of the heart's capacity for regeneration and repair
suggest that these challenges are not insurmountable.
Measurement of
14C in the DNA of individuals born prior
to Cold War era nuclear testing estimates that nearly half of
all cardiomyocytes are exchanged during a normal life span
[110]. Since
14C is incorporated equally by the division of
resident cardiomyocytes and circulating progenitor cells,
carbon dating cannot distinguish the cellular origins of
such impressive turnover. Rather, the phenomenon of cardiac
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transplant confirms that extra-cardiac progenitor cells are
capable of long-term engraftment and survival in the
healthy human heart [111]. Thus, the challenge for cardiac
cell therapy is to strengthen donor cells for the harsh
microenvironment of the infarcted heart.
Ischemic preconditioning has long been recognized as a
means of improving myocardial ischemic tolerance [112]. In
addition to activating survival pathways in cardiomyocytes,
ischemic preconditioning recruits endothelial progenitor cells
to serve as mobile reservoirs of cardioprotective cytokines
[113]. Proponents of cardiac cell therapy now seek to harness
this property to enhance donor cell survival. Hypoxic
preconditioning of mesenchymal stem cells and cardiac
progenitor cells prior to transplant improves not only their
recruitment, survival, and differentiation at the infarct border
zone but also overall ventricular structure and function [114,
115]. Similar benefits might be obtained by hypoxic
preconditioning of endothelial progenitor cells, based on
results from an ischemic hindlimb model [116]. This is
because, in each of these cell types, hypoxic preconditioning
upregulates a diverse array of survival, angiogenic, and
migratory proteins, including HIF-1α, Akt-1, Bcl-2, Ang-1,
VEGF and its receptor Flk-1, SDF-1's receptor CXCR4, and
HGF's receptor c-Met [114, 115, 117]. Together, these factors
allow donor cells not only to endure but also to heal the
injured myocardium.
Extending this concept, hypoxic preconditioning can be
mimicked by genetic modification of donor cells to over-
express hypoxia-responsive survival factors. Akt-1 is acti-
vated by hypoxia and other stimuli, including cytokines. As
a general mediator of survival signaling, Akt-1 is both
necessary and sufficient for cell survival in a variety of
settings [118]. Blockade of Akt-1 activation with the
phosphoinositol 3-kinase (PI3K) inhibitor wortmannin
attenuates the cardioprotective effects of endothelial progen-
itor cell therapy after ischemic injury in pigs [119]. On the
other hand, genetic modification of MSCs to overexpress
Akt-1 results in marked improvement in intracardiac
MSC retention and survival in rat and pig infarct models
[120, 121]. In both species, transplantation of Akt-1-
overexpressing MSCs also normalizes ventricular function.
Follow-up studies have demonstrated that Akt-1-
overexpressing MSCs release paracrine factors that promote
myocardial survival and recovery after infarction [122,
123]. By means of functional genomics, secreted frizzled
related protein 2 (Sfrp2) was identified as the key Akt-1–
MSC-expressed paracrine factor mediating myocardial
survival and repair after ischemic injury [123]. When Sfrp2
is suppressed in Akt-1−MSCs, the ability of these cells to
repair injured myocardium is lost [123]. Alternatively,
genetic modification of MSCs to specifically overexpress
Sfrp2 promotes their retention and survival within the
infarct border zone, as well as facilitates restoration of
cardiac structure and function after infarction [124]. These
benefits may be attributable to Sfrp2-mediated inhibition of
Wnt binding to the frizzled receptor, which results in
accumulation of β-catenin and upregulation of antiapop-
totic and proangiogenic signaling.
Other paracrine factors upregulated in Akt-1−MSCs
include thymosin β4( T β4) and insulin-like growth factor-
1 (IGF-1) [122]. Tβ4 is a secreted, G-actin sequestering, 43
amino-acid peptide that stimulates the migration and
survival of cardiomyocytes and endothelial cells [125], as
well as the migration and differentiation of epicardial
coronary vascular progenitors [126]. After coronary artery
ligation in mice, intramyocardial injection of Tβ4 protein
activates ILK and Akt-1, limits scar formation, and
improves ventricular function [125]. Exemplary of Tβ4's
importance in cell therapy, shRNA-mediated knockdown of
Tβ4 in endothelial progenitor cells blocks the cardiopro-
tective actions of these cells after ischemia-reperfusion in
mice [127].
In addition to stimulating myocardial growth and
contractility, IGF-1 activates the PI3K/Akt-1 pathway to
promote cardiomyocyte survival and proliferation in
response to injury [128, 129]. IGF-1 protein has been
combined with cell therapy to improve donor cell survival
and differentiation in host myocardium [130, 131].
Extending these benefits, IGF-1 cell-based gene therapy
has improved donor cell engraftment and proliferation and
enhanced host cell recruitment to ischemic myocardium
[132, 133]. This has been accompanied by decreased
infarct size, increased angiogenesis, and improved ven-
tricular function. Molecular studies have attributed
IGF-1's therapeutic benefit, in part, to activation of
PI3K/Akt-1 and Bcl-2 and to release of SDF-1 and VEGF
[132, 133].
Downstream of IGF-1 and PI3K/Akt-1, but not Sfrp2
[123], Bcl-2 has been identified as a key antiapoptotic
protein with potential utility in cardiac cell therapy. Bcl-2
preserves mitochondrial integrity during ischemia and is
upregulated by ischemic preconditioning [134]. Cell lines
derived from ESCs which overexpress Bcl-2 self-renew
continuously, even in the absence of serum and feeder cells
[135]. This gives a marked survival advantage to Bcl-2
overexpressing donor cells upon cardiac transplant. Indeed,
MSCs, smooth muscle cells, and cardiomyoblasts geneti-
cally modified to overexpress Bcl-2 have all demonstrated
reduced cell loss and improved ventricular function after
transplant into ischemic myocardium [136–138]. But while
such results may be encouraging, cell-based gene therapy
utilizing cell survival factors is not without its challenges,
as these proteins may predispose to tumorigenesis. Much
work still lies ahead to regulate the expression of these
factors before their clinical application.
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Myocardial regeneration after injury has long been the goal
of cardiac cell therapy. However, recent experience has
shown that cell therapy is capable of providing significant
structural and functional benefit with only minimal cardio-
myocyte regeneration. As we have discussed, donor cells can
recruit host cells to the site of injury, especially if they are
modified to overexpress stem and progenitor cell homing
factors. Donor cells can secrete paracrine factors to promote
host tissue preservation and repair, especially if they are
modified to overexpress survival or growth factors [52, 122,
123, 133], and donor muscle cells can provide contractile
reserve, especially if they are modified to overexpress
connexins essential for electromechanical coupling [139].
Given these capabilities, one might legitimately ask if the last
piece of the cardiac cell therapy puzzle—cardiomyocyte
regeneration—even needs to be solved.
We would argue that cardiomyocyte regeneration
remains a worthy and attainable goal. As we have
discussed, recent measurements of
14C incorporation into
the heart indicate that nature provides for cardiac regener-
ation throughout a normal human lifetime [110]. Our
challenge is to nurture that process after injury. Genetic
fate-mapping studies have shown that nearly 20% of
cardiomyocytes bordering a murine myocardial infarction
are derived from endogenous stem or precursor cell
differentiation [140]. Cell therapy aims to increase that
ratio. This may be accomplished by utilization of more
committed cardiac progenitor cells isolated from the adult
heart or derived in culture from pluripotent stem cells.
The adult heart is home to a side population (SP) of stem
cells identified by exclusion of the vital dyes Hoechst
33342 and rhodamine 123 [141, 142]. Isolated cardiac SP
cells that express stem cell antigen-1 (Sca-1+), but are
negative for the endothelial marker CD31, are capable of
differentiation into functional cardiomyocytes after co-
culture with adult cardiomyocytes [143] or treatment with
a cocktail of bone morphogenetic protein 2, fibroblast
growth factors 4 and 8, the Wnt antagonist Dickkoff-1,
and 5-azacytidine [144]. Transplantation of both pre-
differentiated and undifferentiated Sca-1+/CD31− cells
after myocardial infarction in mice results in efficient
homing, engraftment, and differentiation into cardiomyo-
cytes and endothelial cells, as well as improved ventricular
function [144–146].
A second resident progenitor population comprises c-Kit
(also known as CD117) positive cells, which are located in
small clusters within the adult heart [147]. Isolated c-Kit+
cells do not differentiate into cardiovascular cell types in
culture but showed impressive regenerative potential in
some studies after transplantation into the injured rat heart,
where they gave rise to cardiomyocytes, endothelial cells,
and smooth muscle cells, while also improving ventricular
function [147–150]. However, these results have not been
reproduced in all studies [55]. Nonetheless, a rare Sca-1+/c-
Kit+ cardiac cell type that differentiates into cardiomyo-
cytes upon oxytocin treatment has been identified in mice
[151].
From a technical standpoint, cardiac progenitor cells can
be isolated from mouse hearts and human endomyocardial
biopsies by enzymatic digestion to release round cells that
form so-called cardiospheres in suspension [152, 153].
Cardiosphere-derived cells express endothelial and stem
cell markers, show contractile activity in culture, and can
differentiate into cardiomyocytes, endothelial cells, and
smooth muscle cells. Transplantation of these cells
improves ventricular function after myocardial infarction
in mice and swine, due to both direct cardiomyocyte
regeneration and indirect paracrine action [153–155]. To
test whether these presumably committed cardiac progen-
itor cells have benefit in man, enrollment in the first clinical
trial of “Cardiosphere-derived autologous stem cells to
reverse ventricular dysfunction” (i.e., the CADUCEUS
trial) is now underway [156].
An alternative to laborious isolation of committed cardiac
progenitor cells from the adult heart is differentiation of
committed cardiac progenitor cells from embryonic stem
cells, induced pluripotent stem cells, or other multipotent
cellular resources such as adipose tissue-derived MSCs.
After study of many different growth factor cocktails, a
growing consensus now agrees that modulation of bone
morphogenetic protein (BMP) signaling may be the key to
reliable ex vivo cardiomyocyte differentiation. However,
consensus is lacking with regard to identification of the
critical BMP agonists and antagonists, as well as their
appropriate dosing. Treatment of murine ESCs or MSCs with
BMP2 in the presence of a second growth factor such as
transforming growth factor-β1, fibroblast growth factor 2 or
4, or leukemia inhibitory factor promotes cardiomyocyte
differentiation and improves cardiac structure and function
following transplantation into infarcted myocardium [8, 9,
11, 157]. Similar treatment of human ESCs with BMP4 also
promotes cardiomyogenesis [13]. However, it is also known
that the endogenous BMP antagonist Noggin and the
synthetic BMP inhibitor dorsomorphin also increase cardio-
myocyte differentiation [10–12], in apparent contrast to
studies that blocked the inductive properties of BMP2 and
BMP4 with Noggin [8, 13]. A unifying hypothesis for these
observations suggests that BMP signaling is necessary for at
least two steps in cardiomyocyte development: mesodermal
induction and cardiomyocyte differentiation [158, 159],
between which transient block of BMP signaling is essential
[10]. Thus, the optimal timing and dosage of BMP agonist
and antagonist treatments may be critical. Finally, recent
evidence that adult cardiomyocytes may be induced to
54 J. of Cardiovasc. Trans. Res. (2010) 3:49–60proliferate could provide a complementary strategy for
cardiac regeneration [160].
Ongoing research at the bench and the bedside will
surely continue to perfect these pieces of the cardiac cell
therapy puzzle: comparing sources of donor cells, testing
methods of cell delivery, augmenting myocardial homing,
bolstering cell survival, and promoting cardiomyocyte
differentiation, and while much more work needs to be
done, we have confidence that stem cell therapies in
conjunction with current treatment modalities will ulti-
mately reduce the mortality and improve the quality of life
of patients with cardiovascular disease.
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